PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition

PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition



This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry.

Scope

Who should buy this report?
- This 44-page report gives important, expert insight you wont find in any other source. 26 tables and figures throughout the report illustrate major points and trends. This report is required reading for:
- CMO executives who must have deep understanding of the small molecule API marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

- Overview of contract small molecule API facilities and the proportion of containment and controlled substance specialist capabilities
-Detailed view of the geographic distribution of the small molecule API facilities
- Establishing which CMOs are most involved in contract small molecule API industry by facility count
- Analysis of M&A activity related to small molecule API facilities

2 List of Tables
3 List of Figures
4 Executive Summary
5 Industry Size and Structure
5.1 Definition of the Small Molecule API CMO Universe
5.2 Industry Demographics
6 Top CMOs by Small Molecule API Facilities
6.1 Controlled Substance Small Molecule API Manufacturing Facilities
6.2 Small Molecule API Manufacturing Facilities with Containment
7 Geographical Distribution of Small Molecule Manufacturing Facilities
7.1 Geographical Distribution of Controlled Substance Facilities
7.2 Geographical Distribution of Facilities with Containment Capabilities
7.3 European Analysis
8 Characteristics of the Largest CMOs
9 M&A Activity Involving Small Molecule Contract Manufacturing Facilities
10 The Outlook for the API CMO Industry
11 Notes on Methodology
12 Appendix
12.1 Appendix Tables
12.2 Bibliography
12.3 Primary Research - Key Opinion Leaders in this Report
12.4 About the Authors
12.5 Contact Us
12.6 Disclaimer

List Of Tables

Table 1: Revenue Composition and Specialized Capabilities of Leading CMOs, 2018 25
Table 2: Percentage of Companies by Revenue Tier with Specialized Capabilities (Dedicated Contract and Public CMOs Only)
Table 3: CMO Small Molecule API Manufacturing Facility Acquisitions, 2015-2018 30
Table 4: CMO Small Molecule API Manufacturing Facilities Acquired by Company M&A and Divestment, 2015-2018 30
Table 5: CMO Small Molecule API Manufacturing Facilities Acquired by PE, 2015-2018 31
Table 6: Geographic Reach of CMOs with Small Molecule API Manufacturing, 2018 35
Table 7: Public CMOs API Manufacturing Facilities and Controlled Substance/Containment Capabilities, 2018 40

List Of Figures

Figure 1: Geographic Reach of the Small Molecule API CMO Universe, 2018 (Public CMOs Only) 7
Figure 2: Public CMOs with Small Molecule Manufacturing Capability by Annual Contract Revenue, 2018 8
Figure 3: Geographic Distribution by Headquarters of Public Small Molecule API Dedicated Contract CMOs 9
Figure 4: Top CMOs by Small Molecule API Manufacturing Facilities 10
Figure 5: Top CMOs by Small Molecule API Facilities with Containment Capabilities 11
Figure 6: Top CMOs by Small Molecule API Facilities with Controlled Substance Capabilities 12
Figure 7: Oncology Pipeline by Developmental Stage and Molecule Type 14
Figure 8: Geographical Distribution of All CMO Small Molecule API Manufacturing Facilities 15
Figure 9: Geographical Distribution of Controlled Substance Small Molecule Manufacturing Facilities 17
Figure 10: Geographical Distribution of Small Molecule Manufacturing Facilities with Containment Capabilities 19
Figure 11: NMEs Requiring Special Handling, 2008-2018 20
Figure 12: Geographical Distribution of Small Molecule Contract Manufacturing Facilities in Europe, 2018 21
Figure 13: Distribution of European Small Molecule Contract Manufacturing Facilities with Containment Capabilities, 2018 22
Figure 14: Distribution of Controlled Substance European Small Molecule Contract Manufacturing Facilities, 2018 22
Figure 15: Public CMOs with Small Molecule Manufacturing Capability by Accumulated Contract Revenue, 2018 24
Figure 16: CMO Small Molecule API Manufacturing Facility with Containment Acquisitions, 2015-2018 27
Figure 17: Controlled Substance CMO Small Molecule API Manufacturing Facility Acquisitions, 2015-2018 27
Figure 18: All M&A Deals Involving Small Molecule API Containment Facilities, by Most Active CMOs, 2015-2018 28
Figure 19: All M&A Deals Involving Small Molecule API Controlled Substance Facilities, by Most Active CMOs, 2015-2018 29

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available